Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Prostate cancer in 2011

Redefining the therapeutic landscape for CRPC

Nature Reviews Urology volume 9, pages 63–64 (2012)Cite this article

2011 was a breakthrough year for the treatment of castration-resistant prostate cancer. The encouraging results of two large clinical trials were reported, as well as data identifying a number of promising new therapeutic targets. Bone-modulating agents continued to show potential for the prevention of skeletal events.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Attard, G. & de Bono, J. S. Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Clin. Cancer Res. 17, 3867–3675 (2011).

    Article  CAS  PubMed  Google Scholar 

  3. Scher, H. I. et al. Evaluation of circulating tumor cell enumeration as an efficacy response biomarker of overall survival in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate plus low-dose prednisone post docetaxel [abstract]. J. Clin. Oncol. 29, LBA4517 (2011).

    Google Scholar 

  4. Mulholland, D. J. et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19, 792–804 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Carver, B. S. et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19, 575–586 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Wang, Y. et al. Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers. Oncogene 30, 4327–4338 (2011).

    Article  CAS  PubMed  Google Scholar 

  7. Brenner, J. C. et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19, 664–678 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. de Bono, J., Sandhu, S. & Attard, G. Beyond hormone therapy for prostate cancer with PARP inhibitors. Cancer Cell 19, 573–574 (2011).

    Article  Google Scholar 

  9. Fizazi, K. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377, 813–822 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Parker, C. et al. Overall survival benefit of radium-223 chloride (Alpharadan) in the treatment of patients with symptomatic bone metastasis in castration-resistant prostate cancer: a phase III randomised trial (ALSYMPCA) [abstract LBA1]. Presented at the 16th ECCO-36th ESMO Annual Congress.

Download references

Author information

Authors and Affiliations

  1. Section of Medicine, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Downs Road, Sutton, SM2 5PT, Surrey, UK

    Carmel Pezaro & Gerhardt Attard

Authors
  1. Carmel Pezaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gerhardt Attard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerhardt Attard.

Ethics declarations

Competing interests

G. Attard declares he has been a consultant at Janssen-Cilag, received speakers bureau (honoraria) from Janssen-Cilag, Ipsen and Sanofi-Aventis, received grant/research support (including clinical trials) from AstraZeneca, and is a patent holder/applicant with The Institute of Cancer Research. C. Pezaro declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pezaro, C., Attard, G. Redefining the therapeutic landscape for CRPC. Nat Rev Urol 9, 63–64 (2012). https://doi.org/10.1038/nrurol.2011.235

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2011.235

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing